Equities

BioLife Solutions Inc

BioLife Solutions Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)25.43
  • Today's Change0.42 / 1.68%
  • Shares traded693.99k
  • 1 Year change+86.57%
  • Beta1.8953
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform8
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for BioLife Solutions Inc have a median target of 30.00, with a high estimate of 32.00 and a low estimate of 27.00. The median estimate represents a 18.16% increase from the last price of 25.39.
High26.0%32.00
Med18.2%30.00
Low6.3%27.00

Earnings history & estimates in USD

On Nov 12, 2024, BioLife Solutions Inc reported 3rd quarter 2024 losses of -0.04 per share. This result exceeded the -0.09 consensus loss of the 7 analysts covering the company and exceeded last year's 3rd quarter results by 94.03%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+13.29%
BioLife Solutions Inc reported annual 2023 losses of -1.52 per share on Feb 29, 2024.
Average growth rate-473.41%
More ▼

Revenue history & estimates in USD

BioLife Solutions, Inc. had 3rd quarter 2024 revenues of 30.57m. This bettered the 25.54m consensus of the 9 analysts covering the company. This was 18.92% below the prior year's 3rd quarter results.
Average growth rate-1.91%
BioLife Solutions, Inc. had revenues for the full year 2023 of 143.27m. This was 11.43% below the prior year's results.
Average growth rate+61.95%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.